Glucose Absorption and Gut Hormone Secretion After Gastric Bypass

Not Applicable

• Conditions: Overweight

• Registration Number: NCT03426956
• Lead Sponsor: Hvidovre University Hospital

Brief Summary

To investigate the impact of canagliflozin on secretion of gut hormones, in particular glucagon-like peptide 1 (GLP-1) in gastric bypass operated patients.

Detailed Description

Glucose is a potent stimulus for GLP-1 secretion after gastric bypass surgery and the SGLT-1 transporter appears to be crucial for this response. The study will investigate the effects of SGLT-1/SGLT-2 inhibition (by canagliflozin) on secretion of GLP-1 and other gut hormones after gastric bypass surgery.

Study Timeline

• Status Verified: 2018-02
• Study First Submitted: 2018-02-02
• Study First Submitted QC: 2018-02-02
• Study Start: 2018-02-08
• Study First Posted: 2018-02-08
• Last Update Submitted: 2018-02-08
• Last Update Posted: 2018-02-09
• Primary Completion: 2019-05-01
• Study Completion: 2019-05-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

•Uncomplicated gastric bypass surgery performed minimum 12 months prior to study

Exclusion Criteria

• Type 1 or 2 diabetes mellitus prior to or after gastric bypass surgery
• Pregnancy or breastfeeding
• Haemoglobin levels below 6,5 mM

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
Difference in GLP-1 secretion (evaluated by iAUC).	0-240 min following glucose ingestion	Comparison of the GLP-1 responses (evaluated by iAUC) between the two test days.

Secondary Outcome Measures

Name	Time	Method
Difference in glucose responses between the two test days.	0-240 min following glucose ingestion
Difference in insulin responses between the two test days.	0-240 min following glucose ingestion
Difference in cholecystokinin (CCK) responses (evaluated by iAUC) between the two test days.	0-240 min following glucose ingestion
Difference in bile acid responses (evaluated by iAUC) between the two test days.	0-240 min following glucose ingestion
Difference in C-peptide responses between the two test days.	0-240 min following glucose ingestion
Difference in Gastric Inhibitory Peptide (GIP) responses (evaluated by iAUC) between the two test days.	0-240 min following glucose ingestion
Difference in glucagon responses (evaluated by iAUC) between the two test days.	0-240 min following glucose ingestion
Difference in peptide YY (PYY) responses (evaluated by iAUC) between the two test days.	0-240 min following carbohydrate ingestion
Difference in oxyntomodulin responses (evaluated by iAUC) between the two test days.	0-240 min following carbohydrate ingestion

Trial Locations

Locations (1)

Dept. of Endocrinology; 🇩🇰 Hvidovre, Denmark